 |
| Dr Catherine Carmichael |
Acute Erythroleukaemia (AEL) is an aggressive subtype of Acute Myeloid Leukaemia (AML) with extremely poor outcomes; patients have a less than 20% chance of surviving past five years. AEL is largely resistant to standard treatments and new therapies are desperately needed.
Currently, there is a very limited understanding of the mechanisms that underpin AEL development, and subsequently, scientists and clinicians have made very few inroads into understanding how to best treat this malignancy.
Dr Catherine Carmichael, a group leader at the Australian Centre for Blood Diseases (ACBD), has been awarded $1.38 million by the National Health and Medical Research Council (NHMRC) towards a five-year project investigating novel therapeutic strategies for AEL.
